Neuroinfections and antimicrobials: do we need new molecules or new strategies?
Within last 15 years, analyzing patterns of etiology and resistance in organisms causing neuroinfections, emergence of resistance has been observed in Slovakia in S. haemolyticus to teicoplanin (11%), Ps. aeruginosa and A. baumannii to meropenem (20%) and Candida spp. (non-albicans Candida spp.) to fluconazol (20%). There are no new antibiotics against carbapenem resistant Ps. aeruginosa and Acinetobacter baumannii.
Kalavsky
E
E
St. Elisabeth University, College of Health and Social Sciences, Bratislava, Slovakia.
Kisac
P
P
Huttova
M
M
Benca
J
J
Krcmery
V
V
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001927:Brain Diseases / Q000188:drug therapy / Q000382:microbiology; D002177:Candidiasis / Q000188:drug therapy; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D004352:Drug Resistance, Microbial; D015725:Fluconazole / Q000627:therapeutic use; D006801:Humans; D008581:Meningitis / Q000188:drug therapy* / Q000382:microbiology; D000077731:Meropenem; D011552:Pseudomonas Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D017334:Teicoplanin / Q000627:therapeutic use; D013845:Thienamycins / Q000627:therapeutic use
D000890:Anti-Infective Agents; D013845:Thienamycins; D017334:Teicoplanin; D015725:Fluconazole; D000077731:Meropenem